Plus   Neg

CBMG Up 50% YTD, HAIR Keeps Falling, MNOV To Report NASH Trial Data In April

FEB7 DOWN 020718 lt

The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.

1. Cellular Biomedicine Group Inc. (CBMG)

Lost 11.63% to close Wednesday's (Feb.7) trading at $17.10. Nevertheless, the stock is up 50% year-to-date.

News: No news

Cellular Biomedicine is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases.


The Company currently has ongoing CAR-T phase I clinical trials in China; CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL), CALL-1 for adult Acute Lymphoblastic Leukemia (ALL), and a phase I trial in China for AlloJoin (CBMG's "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis.

Recent event:

On Feb.5, 2018, the Company announced the receipt of a $30.6 million investment from Sailing Capital Overseas Investment Ltd. As part of the transaction, Sailing will appoint a representative to the Company's Board of Directors.

Near-term Catalysts:

-- Top line data readout from phase I clinical trials for CARD-1 and CALL-1 Chimeric Antigen Receptor (CAR) T-cell treatment for Diffuse Large B-Cell Lymphoma (DLBCL) and Acute Lymphoblastic Leukemia (ALL) in the first half of 2018.
-- Final data readout from AlloJoin phase I clinical trial for off-the-shelf Knee Osteoarthritis (KOA) therapy in China in the first half of 2018.

2. Restoration Robotics Inc. (HAIR)

Lost 10.35% to close Wednesday's trading at $4.33.

Restoration Robotics is a medical device company developing and commercializing the ARTAS Robotic Hair Restoration System.

News: No news

3. MediciNova Inc. (MNOV)

Lost 9.49% to close Wednesday's trading at $9.73.

News: The Company has priced an underwritten public offering of 4.42 million shares at a price of $9.05 each. The gross proceeds to MediciNova from this offering are expected to be approximately $40.0 million.

The offering is expected to close on or about February 12, 2018, subject to customary closing conditions.

Near-term Catalyst:

Interim data from a phase II trial of MN-001 in patients with NASH are expected to be presented at the International Liver Congress on April 13, 2018 in Paris, France.

4. Mesa Laboratories Inc. (MLAB)

Lost 8.10% to close Wednesday's trading at $133.28.

News: No news

Recent event:

On Feb.5, 2018, the Company reported a loss and smaller revenue for the third quarter ended December 31, 2017.

Net loss for the third quarter was $11.09 million or $2.93 per share on revenue of $23.67 million in the recent third quarter. This compared with a net income of $3.25 million or $0.84 per share and revenue of $23.84 million in the year-ago quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT